Alnylam Pharmaceuticals, Inc. (BMV:ALNY)

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $773.69M USD in the quarter ending June 30, 2025, with 17.26% growth. This brings the company's revenue in the last twelve months to $2.46B, up 5.01% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.

• Revenue (ttm): $2.46B
• Revenue Growth: +5.01%
• P/S Ratio: 24.11
• Revenue / Employee: $1.10M
• Employees: 2,230
• Market Cap: 1,119.35B MXN

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	2.25B	419.95M	22.97%
Dec 31, 2023	1.83B	790.87M	76.23%
Dec 31, 2022	1.04B	193.13M	22.88%
Dec 31, 2021	844.29M	351.43M	71.31%
Dec 31, 2020	492.85M	273.10M	124.28%
Dec 31, 2019	219.75M	144.84M	193.36%
Dec 31, 2018	74.91M	-15.00M	-16.69%
Dec 31, 2017	89.91M	42.75M	90.66%
Dec 31, 2016	47.16M	6.06M	14.75%
Dec 31, 2015	41.10M	-9.46M	-18.72%
Dec 31, 2014	50.56M	3.39M	7.20%
Dec 31, 2013	47.17M	-19.56M	-29.31%
Dec 31, 2012	66.73M	-16.03M	-19.37%
Dec 31, 2011	82.76M	-17.28M	-17.28%
Dec 31, 2010	100.04M	-492.00K	-0.49%
Dec 31, 2009	100.53M	4.37M	4.54%
Dec 31, 2008	96.16M	45.27M	88.94%
Dec 31, 2007	50.90M	23.97M	89.00%
Dec 31, 2006	26.93M	21.21M	371.13%
Dec 31, 2005	5.72M	-	-